Valeant Enters Female Pharma Field With Sprout Buy
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals will add a new therapeutic area to its portfolio with the $1bn purchase of Sprout Pharmaceuticals two days after the smaller company won US FDA approval for Addyi (flibanserin) to treat women with a low sex drive, but the Canadian acquirer has some catching up to do with leaders in the female pharma field.